毛细胞白血病的基因组分析发现新的复发性遗传学改变
该研究对53例经典型毛细胞白血病(cHCL)和8例变异型毛细胞白血病(vHCL)进行深度靶向突变与拷贝数分析,发现除BRAFV600E外,7q杂合性缺失靶向野生型BRAF,KMT2C失活突变见于15%的cHCL和25%的vHCL,13%的vHCL存在CCND3激活突变或U2AF1功能改变突变;对原发维莫非尼耐药cHCL的分析鉴定出IRS1新发功能获得突变及NF1、NF2缺失。
要点
- cHCL最常见的遗传学改变为7q杂合性缺失,其最小缺失区域靶向野生型BRAF,可将cHCL分为BRAFV600E半合子与杂合子。
- KMT2C失活突变在cHCL中占15%,在vHCL中占25%。
- 13%的vHCL存在CCND3激活突变,13%的vHCL存在U2AF1功能改变突变。
核心结论
- 这些数据进一步揭示了cHCL和vHCL的遗传学基础及临床RAF抑制剂耐药的机制。
研究设计与样本
- 对53例经典型毛细胞白血病(cHCL)和8例变异型毛细胞白血病(vHCL)进行深度靶向突变与拷贝数分析。
主要发现
- cHCL中除BRAFV600E外最常见的遗传学改变为7q杂合性缺失,其最小缺失区域靶向野生型BRAF,可将cHCL分为BRAFV600E半合子与杂合子。
- KMT2C失活突变在cHCL中占15%,在vHCL中占25%。
- 13%的vHCL存在CCND3预测激活突变,13%的vHCL存在U2AF1功能改变突变。
- 对原发维莫非尼耐药cHCL的基因组分析鉴定出IRS1新发功能获得突变及NF1、NF2缺失,各自贡献耐药。
关键数值与推荐
- cHCL中BRAFV600E突变频率接近100%,约30%的vHCL存在MAP2K1突变。
- KMT2C失活突变在cHCL中占15%,在vHCL中占25%。
- 13%的vHCL存在CCND3预测激活突变,13%的vHCL存在U2AF1功能改变突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classical hairy cell leukemia (cHCL) is characterized by a near 100% frequency of the BRAFV600E mutation, whereas ∼30% of variant HCLs (vHCLs) have MAP2K1 mutations. However, recurrent genetic alterations cooperating with BRAFV600E or MAP2K1 mutations in HCL, as well as those in MAP2K1 wild-type vHCL, are not well defined. We therefore performed deep targeted mutational and copy number analysis of cHCL (n = 53) and vHCL (n = 8). The most common genetic alteration in cHCL apart from BRAFV600E was heterozygous loss of chromosome 7q, the minimally deleted region of which targeted wild-type BRAF, subdividing cHCL into those hemizygous versus heterozygous for the BRAFV600E mutation. In addition to CDKN1B mutations in cHCL, recurrent inactivating mutations in KMT2C (MLL3) were identified in 15% and 25% of cHCLs and vHCLs, respectively. Moreover, 13% of vHCLs harbored predicted activating mutations in CCND3 A change-of-function mutation in the splicing factor U2AF1 was also present in 13% of vHCLs. Genomic analysis of de novo vemurafenib-resistant cHCL identified a novel gain-of-function mutation in IRS1 and losses of NF1 and NF2, each of which contributed to resistance. These data provide further insight into the genetic bases of cHCL and vHCL and mechanisms of RAF inhibitor resistance encountered clinically.
引用
- Durham BH, Getta B, Dietrich S, et al. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017. PMID: 28801450. doi:10.1182/blood-2017-01-765107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。